Skip to main content
S&P 5007,740.37+0.23%DOW52,552.78+0.33%NASDAQ26,477.060.00%BTC$80,519.00+0.04%ETH$2,331.81-0.61%GOLD$4,055.90-0.46%OIL$102.76+2.86%
Smart Investors Daily
SID Premium
XE

NASDAQ · XERS

Xeris Biopharma Holdings, Inc.

Healthcare · Biotechnology

$10.45

Up+$0.28 (+2.70%)

Updated Oct 28, 2026, 3:47 PM

SID Score

7.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.16B
P/E ratio
-34.21
Dividend yield
0.00%
52-week range
$5.25 – $11.42
Volume
1.52M
Avg. volume
2.44M

Price performance · XERS

XERS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 27, 2026

XERS closed at $10.45 after 21 trading sessions, up 4.71% for the selected period.

Last close
$10.45
Period change
+4.71%
Period low
$9.08
Period high
$11.13
Daily close
View OHLC price history
XERS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 27, 2026$10.16$10.485$10.10$10.451.52M
Oct 26, 2026$10.22$10.405$10.12$10.211.91M
Oct 23, 2026$10.85$10.85$10.06$10.202.37M
Oct 22, 2026$10.81$10.98$10.67$10.861.41M
Oct 21, 2026$11.14$11.275$10.7701$10.7851.68M
Oct 20, 2026$11.005$11.35$10.9639$11.132.9M
Oct 19, 2026$10.34$11.415$10.34$10.954.34M
Oct 16, 2026$10.04$10.33$9.8401$10.312.29M
Oct 15, 2026$9.77$10.18$9.76$10.071.94M
Oct 14, 2026$10.08$10.39$9.73$9.772.37M
Oct 13, 2026$10.41$10.50$10.15$10.202.22M
Oct 12, 2026$10.465$10.55$10.325$10.461.33M
Oct 9, 2026$10.15$10.60$10.07$10.483M
Oct 8, 2026$10.10$10.35$10.00$10.191.98M
Oct 7, 2026$10.00$10.27$9.91$10.112.22M
Oct 6, 2026$10.23$10.325$9.90$10.072.4M
Oct 5, 2026$9.15$10.235$9.12$10.134.66M
Oct 2, 2026$9.34$9.34$9.035$9.081.8M
Oct 1, 2026$9.52$9.69$9.175$9.253.59M
Sep 30, 2026$9.97$10.07$9.545$9.563.75M
Sep 29, 2026$9.77$11.33$9.50$9.9819.31M

Latest XERS news

The latest Smart Investors Daily articles mentioning XERS.

Stock researchCompany · Overview

XERS research

Overview

Company profile and research snapshot.

Company profile

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$13.50
Implied upside
—
Analysts
12
XERS recent ratings
DateFirmRatingTarget
Oct 6, 2026BarclaysOverweight—
Sep 10, 2026Leerink PartnersOutperform—
Aug 20, 2026BarclaysOverweight—
Mar 2, 2026HC Wainwright & Co.Buy—
Jan 9, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

CHICAGO, October 22, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced it will release its financial results and business highlights for the third quarter ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 5, 2026. Management will host a conference call

Yahoo · Oct 8, 2026

Why Xeris Biopharma Holdings (XERS) Is Up 5.8% After Raising 2026 Revenue Guidance And Retiring Debt

Xeris Biopharma Holdings recently reported a record second quarter, highlighting strong revenue growth led by Recorlev, enhanced intellectual property protections, and the full retirement of its convertible notes, while also raising the lower end of its 2026 total revenue guidance to US$385 million–US$390 million. By simplifying its capital structure and tightening guidance around higher expected revenues, the company has sharpened its longer-term commercial and financial profile for...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By